Date: 2014-02-11
Type of information: R&D agreement
Compound:
Company: Medimmune (USA - global biologics arm of AstraZeneca (UK) Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF - USA)
Therapeutic area: Cancer - Oncology, Cardiovascular diseases, Metabolic diseases, Respiratory diseases, Inflammatory diseases, Autoimmune diseases, Infectious diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On February 11, 2014, MedImmune, the global biologics research and development arm of AstraZeneca, has announced it has entered into a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF). The collaboration will focus on CTSI’s Catalyst Awards program, which solicits applications from University scientists who wish to move their translational research beyond the bench and into product development. This marks the first industrial partnership for CTSI’s Catalyst Awards program’s therapeutic track, which focuses specifically on discovery and development of patient treatment options. The collaboration will benefit both MedImmune’s biologics and AstraZeneca’s small molecule portfolios and will call for proposals in therapeutic areas of interest to MedImmune and AstraZeneca, including cardiovascular and metabolic disease; oncology; respiratory, inflammation and autoimmunity; neuroscience and infectious disease.
MedImmune and UCSF will collaborate to move forward the most promising research projects over the next three years with the option to extend the partnership. The collaboration will foster scientific exchange and expertise between UCSF and MedImmune scientists, and support projects that translate research into treatments that improve patient outcomes.
Financial terms: Financial terms around the collaboration were not disclosed.
Latest news:
